BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:28 PM
 | 
Dec 06, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product led to a lower improvement on the primary endpoint of overall survival (OS) vs. topotecan.

The failure is the second setback this year for the product, which was the centerpiece of AbbVie's 2016 acquisition of Stemcentrx Inc. for $5.8 billion up front and up to $4 billion in milestones.

Read the full 404 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >